ATCT-01 PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RILOTUMUMAB AND BEVACIZUMAB (BEV) IN SUBJECTS WITH RECURRENT MALIGNANT GLIOMA (MG)

Benzer Materyaller

• Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
  Yazar:: Affronti, Mary Lou, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• ATCT-13 BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION: A PHASE II TRIAL
  Yazar:: Weant, Mallika, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• AT-20 SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV)
  Yazar:: Desjardins, Annick, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• AT-19 SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE
  Yazar:: Desjardins, Annick, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL
  Yazar:: Peters, Katherine, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)